|
Methioninase Inducing Virus for Anti-Cancer Therapy
Application
A set of viral constructs that induce regulatable expression of methionine degrading enzyme for treatment of brain tumors.
Key Benefits
Built-in Tet-responsive element ensures precise regulation, preventing unwanted enzyme activity.
IL-2 signal directs the enzyme for secretion, optimizing its therapeutic impact.
Specific delivery...
Published: 1/20/2026
Contributor(s): Timothy R. Gershon, Leon McSwain, Andrey Tikunov
|
|
Small Molecule Inhibitors Targeting OTUD4-CD73 Interaction for Immune-Cold Tumors
Application
This technology introduces small molecule inhibitors, ST80 and Z22, to disrupt the protein-protein interaction (PPI) between OTUD4 and CD73. These inhibitors enhance tumor immunogenicity by reducing CD73 stabilization, improving the immune response in triple-negative breast cancer (TNBC) and other immune-cold tumors.
Key Benefits
ST80...
Published: 1/20/2026
Contributor(s): Yong Wan, Yueming Zhu, Ivet Bahar, Anupam Banerjee, Jiyoung Lee
|
|
Gene Editing for Head and Neck Cancer Treatment
Application
Method for delivering gene-editing therapeutic in head and neck cancers.
Key Benefits
CRISPR/CAS9-based gene editing mechanism targeting novel disease-modifying gene.
Liquid nanoparticle encapsulation permitting in vivo delivery.
Market Summary
Head and neck cancers (HNC) are the 7th most common global cancer, accounting for 3%...
Published: 11/7/2025
Contributor(s): Yong Teng, Yamin Li
|
|
Anticancer Agent with N-Glycan Specificity
Application
An engineered protein for targeting disease-associated N-glycans.
Key Benefits
High affinity, pH insensitive, no cofactors required.
Applications in anticancer and antiviral therapeutics and research.
Can aid in manufacturing monoclonal antibodies with desired N-glycosylation properties.
Market Summary
Glycosylation involves post-translation...
Published: 1/20/2026
Contributor(s): Eric J. Sundberg, Diego Sastre, Maros Huliciak
|
|
Molecules Targeting Inflammatory Signaling
Application
A group of small molecules for treating central and peripheral diseases associated with inflammation.
Key Benefits
Applicable to a wide variety of central nervous system and peripheral diseases.
Can bypass side effects of existing therapeutics targeting similar inflammatory pathways.
High target selectivity and aqueous solubility.
Capability...
Published: 1/20/2026
Contributor(s): Raymond (Ray) Dingledine, Radhika Amaradhi, Shabber Mohammed, Thota Ganesh
|
|
MKK3/MYC Protein-Protein Interaction Inhibitor Overcomes Resistant Non-Small Cell Lung Cancer
Application
A therapeutic use for SGI-1027 in the treatment of Osimertinib-resistant non-small cell lung cancer (NSCLC).
Key Benefits
The MKK3/MYC protein-protein interaction inhibitor SGI-1027 effectively decreases MYC levels in Osimertinib-resistant NSCLC cell lines.
The combination of SGI-1027 with Osimertinib offers synergistic benefits over...
Published: 12/5/2025
Contributor(s): Andrey Ivanov, Haian Fu, Shi-Yong Sun, Zhen Chen
|
|
Enhanced Delivery and Efficacy of Antisense Drugs via Covalently Linked Nanodisc Scaffolds
Application
A synthetic nanodisc (ND) scaffold for delivering antisense oligonucleotides (ASOs) for the treatment of disease.
Key Benefits
Improved cellular uptake and protein suppression using antisense oligos.
Longer ASO half-life compared to other ASO delivery methods.
Potential to overcome the delivery and efficacy challenges using ASOs for...
Published: 1/20/2026
Contributor(s): Khalid Salaita, Radhika Sharma
|
|
Optimizing the Engineering of CAR-T Cells
Application
A method for selecting distinct T cell populations in order to generate more effective CAR-T cells.
Key Benefits
The proposed invention focuses on selecting the optimal “starting material” for the engineering CAR-T cells.
This selection method can be utilized for the development of any and all CAR-T therapies, not limited...
Published: 1/20/2026
Contributor(s): Byron Au-Yeung
|
|
Indolium 1 for Advanced Melanoma Treatment
Application
A small molecule compound for the treatment of melanoma.
Key Benefits
Novel small molecule compound for the treatment of resistant melanoma.
Well tolerated in vivo.
Market Summary
Malignant melanoma is a type of skin cancer that begins in melanocyte cells. Melanoma is the 19th most commonly occurring cancer. Exposure to UV radiation...
Published: 7/22/2025
Contributor(s): Jack Arbiser
|
|
Drug Platform for L-Asparaginases for the Treatment of Leukemias
Application
A novel humanized therapeutic L-asparaginase compound to treat acute lymphoblastic leukemia (ALL) and other cancers.
Key Benefits
A novel drug discovery platform for developing asparaginase-based compounds to treat leukemias and other cancers.
The derivatives could exhibit less immunogenicity and systemic toxicity than FDA-approved...
Published: 1/20/2026
Contributor(s): Sunil Raikar, Christopher Doering, H. (Harold) Trent Spencer, Kristopher Knight, Harrison Brown
|
